Home › Funds › Frazier Life Sciences Management, L.P. › AUTL
Frazier Life Sciences Management, L.P. position in AUTL
AUTOLUS THERAPEUTICS LTD · Health Care
Frazier Life Sciences Management, L.P. reported holding 4,447,910 shares of AUTL (AUTOLUS THERAPEUTICS LTD) in its Q2 2026 13F filing — a position valued at US$7.1M, representing 0.15% of its reported portfolio and ranking #39 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed AUTL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Frazier Life Sciences Management, L.P.'s AUTL position evolved
Frazier Life Sciences Management, L.P. first disclosed a stake in AUTL in Q3 2023 at 3,746,857 shares (US$8.7M). The position peaked in Q1 2024 at 4,623,324 shares, worth US$29.5M. Across 12 filings, Frazier Life Sciences Management, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 4,447,910 shares valued at US$7.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.75M | $8.73M | New |
| Q4 2023 | 3.75M | $24.13M | Hold |
| Q1 2024 | 4.62M | $29.50M | Add |
| Q2 2024 | 4.62M | $16.09M | Hold |
| Q3 2024 | 4.62M | $16.78M | Hold |
| Q4 2024 | 4.62M | $10.86M | Hold |
| Q1 2025 | 4.62M | $7.17M | Hold |
| Q2 2025 | 4.62M | $10.54M | Hold |
| Q3 2025 | 4.62M | $7.54M | Hold |
| Q4 2025 | 4.62M | $9.20M | Hold |
| Q1 2026 | 4.45M | $6.14M | Reduce |
| Q2 2026 | 4.45M | $7.12M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AUTL and 13F data
AUTL (AUTOLUS THERAPEUTICS LTD) is a Health Care company. 18 other funds we track also report a position in AUTL — the largest reported positions include MAK CAPITAL ONE LLC (US$53.8M), Syncona Portfolio Ltd (US$26.6M), ARMISTICE CAPITAL, LLC (US$24.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AUTL
- MAK CAPITAL ONE LLC 33.62M sh · $53.79M · Q2 2026
- Syncona Portfolio Ltd 16.64M sh · $26.63M · Q2 2026
- ARMISTICE CAPITAL, LLC 15.00M sh · $24.00M · Q2 2026
- Tetragon Partners GP Ltd 9.50M sh · $15.20M · Q2 2026
More on Frazier Life Sciences Management, L.P.
FAQ
How long has Frazier Life Sciences Management, L.P. held AUTL?
Frazier Life Sciences Management, L.P. has disclosed AUTL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Frazier Life Sciences Management, L.P.'s current position in AUTL?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 4.45M shares of AUTL (AUTOLUS THERAPEUTICS LTD), valued at $7.12M, representing 0.15% of its reported portfolio and ranking #39.
Has Frazier Life Sciences Management, L.P. been buying or selling AUTL?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in AUTL. The position peaked in Q1 2024 at 4.62M shares.
Which other funds hold AUTL?
Other major institutional holders of AUTL include MAK CAPITAL ONE LLC, Syncona Portfolio Ltd, ARMISTICE CAPITAL, LLC, among 18 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.